menu
    • menu
    [{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein Biosynthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ASEP Medical \/ Bohai Biomedical Technology Development Co.","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ Bohai Biomedical Technology Development Co."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TNF-alpha receptor","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AFYX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AFYX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RXRG001","moa":"hAQP1 overexpression","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Intraductal Injection","sponsorNew":"RiboX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"RiboX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M1 receptor","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"AAV-AQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Sanofi"}]

    Find Clinical Drug Pipelines for Dental and Oral Health

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RiboX Therapeutics

                            China arrow
                            APS Symposium
                            Not Confirmed

                            RiboX Therapeutics

                            China arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXRG001

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RiboX Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001

                            Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.

                            Product Name : RXRG001

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 09, 2025

                            Lead Product(s) : RXRG001

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            APS Symposium
                            Not Confirmed

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyloris Enrolls First Patient in Phase 3 for Proprietary Mouth Rinse for Dental Bleeding

                            Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.

                            Product Name : HY-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MeiraGTx

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            MeiraGTx

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-AQP1

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategi...

                            Details : Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.

                            Product Name : AAV-AQP1

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : AAV-AQP1

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ORAPHARMA

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Approved FDF

                            Sponsor : Bausch Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Clinical Study Suggests the Use of OraPharma’s ARESTIN® (minocycline HCl) Microspheres, 1mg May Decreas...

                            Details : ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

                            Product Name : Arestin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Approved FDF

                            Sponsor : Bausch Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ORAPHARMA

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            ORAPHARMA

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrea...

                            Details : Arestin® (minocycline hydrochloride) is a member of the tetracycline class of antibiotics, a bacteriostatic that exerts its antimicrobial activity by inhibiting protein synthesis, in adults with periodontitis.

                            Product Name : Arestin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RxOMEG Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            RxOMEG Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

                            Details : Pilocarpine is a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiother...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 02, 2023

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ASEP Medical

                            Canada arrow
                            APS Symposium
                            Not Confirmed

                            ASEP Medical

                            Canada arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Bohai Biomedical Technology Development Co.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility...

                            Details : The agreement permits Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient. The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an or...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Bohai Biomedical Technology Development Co.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AFYX Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            AFYX Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodeg...

                            Details : The study showed that a) Rivelin patch was formulated with therapeutic anti-TNFα antibody fragments, b) those fragments were successfully delivered directly to inflamed mucosal tissue, and c) that the antibodies maintained a neutralizing effect on infla...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 09, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth